Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer
Titel:
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer
Auteur:
Schöffski, P. Thate, B. Beutel, G. Bolte, O. Otto, D. Hofmann, M. Ganser, A. Jenner, A. Cheverton, P. Wanders, J. Oguma, T. Atsumi, R. Satomi, M.